Brokerages Set Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) PT at $117.67

Mirum Pharmaceuticals, Inc. (NASDAQ:MIRM) has been given a consensus rating of “Moderate Buy” by the fourteen analysts that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a sell rating, twelve have assigned a buy rating and one has issued a strong buy rating on the company. The average 12 month price target among brokerages that have issued a report on the stock in the last year is $117.6667.

A number of equities research analysts recently issued reports on MIRM shares. Evercore set a $126.00 target price on Mirum Pharmaceuticals in a research note on Wednesday, March 4th. Citizens Jmp reduced their target price on Mirum Pharmaceuticals from $140.00 to $132.00 and set a “market outperform” rating on the stock in a research note on Thursday, February 26th. TD Cowen upped their target price on Mirum Pharmaceuticals from $117.00 to $125.00 and gave the company a “buy” rating in a research note on Friday, March 27th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Mirum Pharmaceuticals in a research note on Thursday, January 22nd. Finally, Royal Bank Of Canada reduced their target price on Mirum Pharmaceuticals from $130.00 to $128.00 and set an “outperform” rating on the stock in a research note on Thursday, February 26th.

Insider Activity at Mirum Pharmaceuticals

In other Mirum Pharmaceuticals news, Director Patrick J. Heron purchased 131,425 shares of Mirum Pharmaceuticals stock in a transaction on Friday, January 23rd. The shares were bought at an average price of $68.48 per share, with a total value of $8,999,984.00. Following the purchase, the director directly owned 459,010 shares in the company, valued at $31,433,004.80. This trade represents a 40.12% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, COO Peter Radovich sold 16,515 shares of the stock in a transaction on Monday, March 16th. The stock was sold at an average price of $91.98, for a total value of $1,519,049.70. Following the transaction, the chief operating officer directly owned 40,272 shares in the company, valued at approximately $3,704,218.56. This represents a 29.08% decrease in their position. The SEC filing for this sale provides additional information. Over the last quarter, insiders have sold 121,942 shares of company stock worth $11,416,645. Company insiders own 14.36% of the company’s stock.

Institutional Inflows and Outflows

A number of large investors have recently made changes to their positions in the business. Janus Henderson Group PLC lifted its stake in shares of Mirum Pharmaceuticals by 21.4% during the 4th quarter. Janus Henderson Group PLC now owns 6,065,308 shares of the company’s stock worth $479,050,000 after purchasing an additional 1,067,722 shares during the period. Eventide Asset Management LLC lifted its stake in shares of Mirum Pharmaceuticals by 4.4% during the 2nd quarter. Eventide Asset Management LLC now owns 2,637,485 shares of the company’s stock worth $134,224,000 after purchasing an additional 110,485 shares during the period. Vanguard Group Inc. lifted its stake in shares of Mirum Pharmaceuticals by 2.0% during the 4th quarter. Vanguard Group Inc. now owns 2,596,089 shares of the company’s stock worth $205,065,000 after purchasing an additional 50,720 shares during the period. State Street Corp lifted its stake in shares of Mirum Pharmaceuticals by 59.2% during the 4th quarter. State Street Corp now owns 2,143,992 shares of the company’s stock worth $169,354,000 after purchasing an additional 797,088 shares during the period. Finally, Price T Rowe Associates Inc. MD lifted its stake in shares of Mirum Pharmaceuticals by 10.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 1,420,375 shares of the company’s stock worth $112,196,000 after purchasing an additional 137,087 shares during the period.

Mirum Pharmaceuticals Price Performance

MIRM stock opened at $96.24 on Friday. Mirum Pharmaceuticals has a 1 year low of $36.88 and a 1 year high of $109.28. The company has a debt-to-equity ratio of 0.98, a quick ratio of 2.55 and a current ratio of 2.67. The stock’s 50 day moving average price is $96.28 and its 200 day moving average price is $82.59. The firm has a market cap of $5.81 billion, a P/E ratio of -200.50 and a beta of 0.51.

Mirum Pharmaceuticals (NASDAQ:MIRM) last posted its earnings results on Wednesday, February 25th. The company reported ($0.11) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.02 by ($0.13). Mirum Pharmaceuticals had a negative net margin of 4.48% and a negative return on equity of 8.53%. The company had revenue of $148.93 million during the quarter, compared to analysts’ expectations of $141.78 million. During the same period in the previous year, the company posted $1.00 EPS. Mirum Pharmaceuticals’s quarterly revenue was up 49.8% compared to the same quarter last year. On average, sell-side analysts expect that Mirum Pharmaceuticals will post -1.43 earnings per share for the current fiscal year.

About Mirum Pharmaceuticals

Mirum Pharmaceuticals, Inc is a late-stage biopharmaceutical company dedicated to the development and commercialization of innovative therapies for rare cholestatic liver diseases. The company’s primary focus lies in addressing the unmet medical needs of patients suffering from genetic and progressive forms of pediatric liver disorders, where limited treatment options currently exist.

Mirum’s lead product candidate, maralixibat (Livmarli), is an ileal bile acid transporter inhibitor designed to reduce systemic bile acid accumulation and alleviate associated pruritus and liver damage.